Convergence of Care – A New Strategy to Reduce Cardiovascular Events

時間: 114.11.01 (星期六) 14:00-16:20

地點: 高雄漢來大飯店 15 樓會展廳 (高雄市前金區成功一路 266 號)

(CME Agenda)

14:00-14:05 (5”)	**Opening Remarks**	林宗憲	
14:05-14:35 (30”)	**The Heart’s Compass — Biomarkers to Guide CV Risk Reduction**	林柏霖	林宗憲
14:35-15:05 (30”)	**The Comorbidity Continuum — The CKD and T2D Path to CV Events**	王宇澄	王朝平
15:05-15:25 (20”)	**Post-lecture poll and Q&A**	林柏霖 林宗憲 王宇澄 王朝平	
15:25-15:35 (10”)	**Break**		
15:35-16:05 (40”)	**The Heart Knight Rises — A New Pillar in HFpEF/HFmrEF**	張瑋婷	郭風裕
16:05-16:15 (10”)	**Post-lecture poll and Q&A**	張瑋婷 郭風裕	
16:15-16:20 (5”)	**Closing Remarks**	郭風裕	

The Heart's Compass - Biomarkers to Guide CV Risk Reduction

林柏霖 醫師

Cardiovascular diseases (CVD), such as heart failure (HF), pose a significant global disease burden, affecting over 60 million individuals worldwide. In recent years, the treatment concept of cardiovascular-kidney-metabolic (CKM) has gained traction, emphasizing the importance of prevention in avoiding the onset of CVD, particularly in patients with type 2 diabetes (T2D) or chronic kidney disease (CKD). To better recognize and promptly mitigate exposure to higher risks, effective biomarkers for risk assessment are essential. According to the 2023 AHA CKM Presidential Advisory screening recommendations, monitoring CKM risk can be enhanced through kidney-related biomarkers such as urinary albumin-to-creatinine ratio (UACR), as well as common CV biomarkers like NT-proBNP, high-sensitivity cardiac troponins, and high-sensitivity C-reactive protein (hs-CRP). In assessing the risk of HF, all four aforementioned biomarkers demonstrate strong correlations with risk. Notably, UACR and NT-proBNP show consistent associations with both HFrEF and HFpEF.

The non-steroidal mineralocorticoid receptor antagonist (finerenone) has exhibited significant effects on these two biomarkers in completed phase III trials (FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF). For example, in the FINEARTS-HF population with HFmrEF/HFpEF, finerenone significantly reduced NT-proBNP levels by 12.1% at three months and continued to decline to 12.5% (both $p<0.001$) by twelve months compared to placebo. From the CKM perspective, significant reductions of 18% and 24% in NT-proBNP were observed at four months in the T2D and CKD populations of the FIDELITY-BNP and FIGARO-BM studies, respectively. Furthermore, in the FIDELITY trial, finerenone achieved a notable 32% reduction in UACR among T2D and CKD patients after four months of treatment.

In contrast to NT-proBNP, currently, the Taiwan government allows for up to four UACR screenings per year for patients enrolled in the Diabetes and Early Chronic Kidney Disease Integrated Care Program, which greatly supports the treatment and management of CKM diseases. Therefore, UACR should be regarded as a critical biomarker in clinical practice.

The Heart Knight Rises – A New Pillar in HFpEF/HFmrEF

張瑋婷 醫師

Treating patients with HFmrEF/HFpEF presents a clinical dilemma due to the heterogeneity of the patient population and limited evidence-based therapies. Unlike HFrEF, where treatment guidelines are well-established, HFmrEF/HFpEF lacks universally effective interventions. Comorbidities such as atrial fibrillation, diabetes, and chronic kidney disease further complicate management. Symptom burden and hospitalization risks remain high, yet response to conventional therapies is often variable. The need for tailored treatment strategies is critical, highlighting the importance of emerging therapies like finerenone, which show promise in improving cardiovascular outcomes and renal function across diverse patient subgroups. The FINEARTS-HF and FINE-HEART sub-analyses provide compelling evidence for the efficacy and safety of finerenone in patients with HFmrEF/HFpEF. Finerenone treatment significantly lowered the risk of the primary outcome—comprising cardiovascular (CV) death and heart failure (HF) events—by 16% compared to placebo, with consistent benefits across all prespecified subgroups. Notably, these positive outcomes were independent of baseline atrial fibrillation (AF) status or AF type, emphasizing finerenone's broad applicability. Also, finerenone's therapeutic effect extended across sex, age, and SGLT-2 inhibitor use, reinforcing its role in comprehensive HF management. Additionally, the drug demonstrated renal benefits by reducing albuminuria and delaying the onset of micro- and macroalbuminuria. In this talk, I will review the latest information regarding the treatment for patients with HFmrEF/HFpEF.

林柏霖醫師

MD，MSc，PhD



連絡資訊

Berlin831@gmail.com

現職

新竹馬偕紀念醫院

資深心臟內科主治醫師

個人學歷

國立陽明交通大學生物科技研究所博士
中原大學生物醫學工程研究所碩士
中山醫學大學醫學系

工作領域

中華民國內科專科醫師
中華民國心臟專科醫師
中華民國心臟專科指導醫師
中華民國介入性心臟學會專科醫師
中華民國心臟電生理暨介入性治療專科醫師
。

教職領域

馬偕醫護管理專科學校講師

馬偕醫護管理專科學校助理教授

學會領域

中華民國心臟學會副秘書長(2022-迄今)

台灣心肌梗塞學會學術委員會委員(2022-迄今)

中華民國心律醫學會財務委員會委員(2020-迄今)

中華民國心律醫學會網站新知委員會委員(2020-2022)

CURRICULUM VITAE
Yu-Chen Wang, M.D., Ph.D.
Asia University Hospital

EDUCATION:

High School: Taichung First Senior High School, Taichung, Taiwan
August 1991 – June 1994

Medical School: National Yang Ming Chiao Tung University, Taipei, Taiwan
October 1994 – June 2001

PhD study: Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
September 2010 – July 2016

POSTGRADUATE TRAINING:

Internship: Taichung Veterans General Hospital, Taichung, Taiwan
November 1999 – June 2001

Residency in Internal Medicine: National Taiwan University Hospital, Taipei, Taiwan
July 2003 – June 2006

Fellowship in Cardiology: National Taiwan University Hospital, Taipei, Taiwan
July 2006 – June 2008

Research Fellow in Cardiology: Texas Heart Institute, Texas, U.S.A.
July 2011 – June 2012

EMPLOYMENTS:

- Director of Internal Medicine Department: Asia University Hospital, Taichung, Taiwan: **July 2021 to present**
- Director of Cardiology Division, Asia University Hospital, Taichung, Taiwan: **August 2016 to present**
- Associated Professor, Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan: **August 2022 to present**
- Adjunct Attending Physician of Preventive Cardiology Section, Division of Cardiology, China Medical University Hospital, Taichung, Taiwan: **May 2019 to present**
- Adjunct Assistant Professor, College of Medicine, China Medical University, Taichung, Taiwan: **2017 to present**
- Director of Taiwan Society of Lipids and Atherosclerosis: **2021 to present**

- Secretary General of Taiwan Myocardial Infarction Society: **2024 to present**
- Chairman of Editorial & Digital Board of Taiwan Society of Cardiovascular Interventions: **2024 to present**
- Academic committee, Educational committee, Research and Registration committee member of Taiwan Society of Cardiovascular Interventions: **2024 to present**
- Academic committee / Guideline and Consensus committee member of Taiwan Society of Cardiology: **2022 to present**
- Member representative of Taichung Medical Association: **2023 to present**

BOARD CERTIFICATION:

Board of Medical Doctor (2001)
Board of Internal Medicine (2006)
Board of Cardiology (2008)
Board of Interventional Cardiology (2009)
Certified Instructor of Cardiology Training Program (2015)

INTERESTED RESEARCH SUBJECTS:

Cellular biology of electronegative low-density lipoprotein
Intervention and pharmacotherapy in acute myocardial infarction
Artificial Intelligence in cardiovascular field

Professional Affiliation:

Member of Taiwan Society of Internal Medicine
Member of Taiwan Society of Cardiology
Member of Taiwan Society of Cardiovascular Interventions

Curriculum Vitae

Name: 張瑋婷 Wei-Ting Chang, M.D., PhD
Office Address: Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, 901, Chung-Hwa Road, Yung-Kang City, Tainan, Taiwan.

Google Scholar https://scholar.google.com/citations?user=AoYbqGQAAAAJ&hl=zh-TW

Education and Experience

2000/9 – 2007/6 **Department of Medicine, National Cheng Kung University, Tainan, Taiwan**
Doctor of Medicine, 2007

2013/9 –2014/8 **Brigham and Women's Hospital, Harvard University, MA, USA**
Research Fellow, Cardiac Muscle Research Laboratory

2019/8 – 2023/06 **Graduate Institute of Clinical Medicine, National Cheng Kung University, Taiwan**
PhD

2023/07 **Visiting Scholar with certificate of Precisional Medicine in St. Edmund Hall, Oxford (OXCEP)**

Professional Experience

2014/8- **Chi-Mei Medical Center, Tainan, Taiwan**
Attending physician, Department of Cardiology

2017/8- **Chi-Mei Medical Center, Tainan, Taiwan**
Director and Principal Investigator, Circulation Lab

2023/8- **Chi-Mei Medical Center, Tainan, Taiwan**
Director, Cardio-Oncology Center

2017/8-202/7 **Southern Taiwan University of Science and Technology, Taiwan**
Assistant Professor, Department of Biotechnology

2020/08- **Southern Taiwan University of Science and Technology, Taiwan**
Associate Professor, Department of Biotechnology

2023/08 **National Sun Yat-sen University, Taiwan**
Associate Professor, Department of Clinical Medicine

2014/8- **Chi-Mei Medical Center, Tainan, Taiwan**
Principal Investigator or Co-PI of more than 30 clinical trials

Awards and Honors

2017-2019 The best annual research award in Chi-Mei Medical Center

2018 TA-YOU WU MEMORIAL AWARD **(吳大猷先生紀念獎)**

2017 Young investigator award in Taiwan Society of Cardiology

2023 The Phi Tau Phi Scholastic Honor (斐陶斐榮譽會員)